生物活性 | |||
---|---|---|---|
描述 | FN-1501 is a potent inhibitor of FLT3 and CDK, with IC50s of 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively; has anticancer activity. |
临床研究 | |||||
---|---|---|---|---|---|
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT03690154 | Advanced Cancer ... 展开 >> Solid Tumor 收起 << | Phase 1 | Recruiting | August 2019 | United States, Kansas ... 展开 >> KUMC Cancer Center Recruiting Fairway, Kansas, United States, 66205 Contact: Stephen K Williamson, MD 913-945-5059 swilliam@kumc.edu Principal Investigator: Stephen K Williamson, MD United States, Michigan Karmanos Cancer Institute Recruiting Detroit, Michigan, United States, 48334 Contact: Ulka Vaishampayan, MD 248-538-4701 vaishamu@karmanos.org Principal Investigator: Ulka Vaishampayan, MD Australia, Victoria Cabrini Malvern Hospital Recruiting Malvern, Victoria, Australia, 3144 Contact: Gary E Richardson, MD 1 300-300-977 gary.richardson@ocv.net.au Principal Investigator: Gary E Richardson, MD 收起 << |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.32mL 0.46mL 0.23mL |
11.59mL 2.32mL 1.16mL |
23.18mL 4.64mL 2.32mL |